

## **The Promise and Perils of ARV-based prevention: Making it a reality on the ground**

Satellite Session at AIDS2010

Sunday, 18 July 2010

15:45 to 17:45

Mini Room 6

**Co-sponsors:** AVAC, Georgetown University, Imperial College, IAS/Industry Liason Forum, WHO

ARV-based prevention – including oral pre-exposure prophylaxis (PrEP), ARV-based topical microbicides and the possibility of “treatment as prevention – is widely viewed as one of the more promising biomedical HIV prevention strategies under study today.

However, even if current clinical trials demonstrate efficacy among some populations, formidable challenges remain to demonstrate its effectiveness and feasibility. Implementing ARV-based prevention raises questions for virtually every aspect of existing AIDS responses, from how to integrate it within existing HIV testing and counselling, prevention and treatment interventions, to how individual and community risk is conceptualized and addressed. It will also raise challenges to policymakers and programme managers regarding how to allocate limited health care resources in order to optimize their impact on health outcomes.

This session will provide an opportunity for various stakeholders to discuss what needs to happen beyond the current research, including additional research priorities (such as other potential ARV-based prevention candidates and intermittent dosing strategies) and the operational, financial and ethical issues that will need to be addressed in order to translate positive safety and efficacy findings into delivery programmes that will have a public health impact at the country level.

The session is designed to initiate debate and dialogue on the opportunities and challenges of ARV-based prevention and discuss what is possible, what is needed and how ARV-based prevention fits into the broader landscape of prevention and treatment services aimed at slowing the epidemic worldwide.

### **Programme**

Welcome/introduction:

Elly Katabira, IAS

Moderators/facilitators:

Mark Dybul, Georgetown University

Ying-Ru Lo, WHO

Peter Piot, Imperial College

James Rooney, Gilead

Mitchell Warren, AVAC: Global Advocacy for HIV Prevention

*Topical, oral; daily, intermittent; single or combination-agents – what do we need and what will work?*

Patrick Ndase, International Clinical Research Center

*Who Gets What? The Challenges of Delivering ARVs for Prevention and Treatment*

Helen Rees, RHRU

*Be careful what you wish for – are we ready for ARV-based prevention? If not, what do we need to do!*

Vuyiseka Dubula, Treatment Action Group

*Beyond the trials: Translating research results into public health impact (an update on modeling)*

Catherine Hankins, UNAIDS

Each presenter will be introduced by one of the moderators/facilitators and invited to give a 15- to 20-minute presentation. This should take approximately 90 minutes in total with introductions. There will then be 30-minute facilitated discussion amongst the panelists and facilitators and with the audience.